FISH OIL AND GEMCITABINE IN PANCREATIC ADENOCARCINOMA - VERSION 1

• Research type

  Research Study

• Full title

  PHASE II TRIAL OF THE EFFECT OF GEMCITABINE WITH INTRAVENOUS OMEGA-3 FISH OIL INFUSION IN PATIENTS WITH UNRESECTABLE PANCREATIC ADENOCARCINOMA.

• IRAS ID

  9222

• Sponsor organisation

  R & I Office

• Eudract number

  2009-009470-27

• ISRCTN Number

  n/a

• Clinicaltrials.gov Identifier

  n/a

• Research summary

  Pancreatic cancer is the fifth most common cause of cancer-related deaths in the United Kingdom. Despite improvements in surgery and chemotherapy, it has one of the worst outcomes of all gastrointestinal malignancies, and remains largely resistant to the current chemotherapy agent of choice, gemcitabine. Omega-3 fatty acids, found in fish oils, have been shown to several potential benefits in laboratory and animal pancreatic cancer experiments, including reducing growth and spread of pancreatic cancer. In addition, oral omega-3 fish oil supplements have been shown to improve quality of life in patients with advanced pancreatic cancer.More recently, laboratory experiments have shown omega-3 fish oils to promote the anti-cancer effects of gemcitabine in pancreatic cancer cells. The aim of this trial is to assess the combination of omega-3 fish oils and gemcitabine in patients with advanced pancreatic cancer. It is hoped that similar to the laboratory experiments, that omega-3 fish oils will improve the anticancer effects of gemcitabine in these patients, thus potentially improving their prognoses.

• REC name

  East Midlands - Nottingham 2 Research Ethics Committee

• REC reference

  09/H0408/51

• Date of REC Opinion

  1 Jun 2009

• REC opinion

  Further Information Favourable Opinion